Cholesterol efflux protein, ABCA1, supports anti-cancer functions of myeloid immune cells

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Solid tumors often resist immune therapy due to suppressive myeloid cells (MCs), like macrophages.
• Cholesterol metabolism in MCs impacts cancer progression and treatment outcomes.
• Identifying MC-specific targets regulating cholesterol is crucial for improving cancer immunotherapy.

Purpose of the Study:

• To identify MC-expressed proteins involved in cholesterol homeostasis and linked to patient survival.
• To investigate the role of the cholesterol efflux protein ABCA1 in anti-tumor immunity.
• To explore ABCA1's potential as a therapeutic target for overcoming cancer immune evasion.

Main Methods:

• Screening for MC proteins involved in cholesterol homeostasis and survival association.
• Preclinical studies assessing ABCA1 activity in macrophage anti-cancer functions.
• Analysis of ABCA1 expression in human blood and breast tumors, correlating with immune markers and angiogenesis.
• Generating myeloid cell-specific ABCA1 knockout mice to evaluate tumor growth and metastasis.

Main Results:

• ABCA1 was identified as a key cholesterol efflux protein in myeloid cells.
• ABCA1 activity enhanced macrophage anti-tumor functions, including tumor infiltration and CD8+ T cell support.
• ABCA1 expression correlated with reduced angiogenic potential (VEGFA) and increased CD8+ T cell activity in human tumors.
• Loss of ABCA1 in myeloid cells accelerated tumor growth and metastasis in mice.

Conclusions:

• ABCA1 plays a critical role in regulating myeloid cell function and anti-tumor immunity.
• ABCA1's influence on cholesterol metabolism directly impacts cancer progression and immune surveillance.
• Targeting ABCA1 in myeloid cells presents a promising novel strategy to enhance cancer immune therapy and combat resistance.